{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:49:12Z","timestamp":1795031352599,"version":"4.10.2"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC32530059"],"award-info":[{"award-number":["NSFC32530059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC82202320"],"award-info":[{"award-number":["NSFC82202320"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC31771096"],"award-info":[{"award-number":["NSFC31771096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital of Sichuan University","doi-asserted-by":"publisher","award":["19HXBH099"],"award-info":[{"award-number":["19HXBH099"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC1585"],"award-info":[{"award-number":["2023NSFSC1585"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biomaterials.2026.124026","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:26:35Z","timestamp":1769844395000},"page":"124026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Genetically engineered cellular membrane-camouflaged nanoparticles amplify immune response against recurrent metastatic triple-negative breast cancer"],"prefix":"10.1016","volume":"330","author":[{"given":"Yun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwu","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-6103","authenticated-orcid":false,"given":"Bingyang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-3027","authenticated-orcid":false,"given":"Zhiyong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2026.124026_bib1","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ Br. Med. J."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124026_bib3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics","volume":"72","author":"Giaquinto","year":"2022","journal-title":"Ca-Cancer J. Clin."},{"key":"10.1016\/j.biomaterials.2026.124026_bib4","first-page":"93","article-title":"Triple-negative breast cancer: treatment challenges and solutions","volume":"8","author":"Collignon","year":"2016","journal-title":"Breast cancer"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124026_bib5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3322\/caac.21728","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"Ca-Cancer J. Clin."},{"key":"10.1016\/j.biomaterials.2026.124026_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257452","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/PD-L1 expression are linked in breast cancer","volume":"6","author":"Buisseret","year":"2016","journal-title":"OncoImmunology"},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124026_bib8","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: a review of current evidence and prognostic implications from pathologist's perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124026_bib9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/jpm13071176","article-title":"Immune biomarkers in triple-negative breast cancer: improving the predictivity of current testing methods","volume":"13","author":"Porta","year":"2023","journal-title":"J. Personalized Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124026_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of immunotherapy in triple-negative breast cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124026_bib11","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.gendis.2022.07.024","article-title":"Targeting PD-1\/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients","volume":"10","author":"Kumar","year":"2023","journal-title":"Genes Dis."},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124026_bib12","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10265","key":"10.1016\/j.biomaterials.2026.124026_bib13","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124026_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124026_bib16","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.7150\/thno.80091","article-title":"Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy","volume":"13","author":"Yin","year":"2023","journal-title":"Theranostics"},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124026_bib17","article-title":"PD-1 blockade cellular vesicles for cancer immunotherapy","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41392-024-01859-4","article-title":"Genetically programmable cell membrane-camouflaged nanoparticles for targeted combination therapy of colorectal cancer","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"Pt 3","key":"10.1016\/j.biomaterials.2026.124026_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semcancer.2022.02.010","article-title":"Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer","volume":"86","author":"Wang","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124026_bib20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124026_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","article-title":"Metabolic instruction of immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib22","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41467-020-18626-y","article-title":"Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis","volume":"11","author":"Rao","year":"2020","journal-title":"Nat. Commun."},{"issue":"50","key":"10.1016\/j.biomaterials.2026.124026_bib23","doi-asserted-by":"crossref","first-page":"26320","DOI":"10.1002\/anie.202108342","article-title":"Genetically programmable fusion cellular vesicles for cancer immunotherapy","volume":"60","author":"Meng","year":"2021","journal-title":"Angewandte Chemie (International ed. in English)"},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124026_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12379","article-title":"Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124026_bib27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-L\u00f3pez","year":"2019","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124026_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108500","article-title":"Lactate limits T cell proliferation via the NAD(H) Redox State","volume":"33","author":"Quinn","year":"2020","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124026_bib29","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124026_bib30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1","volume":"35","author":"Wu","year":"2023","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","article-title":"Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer","volume":"28","author":"Li","year":"2018","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124026_bib32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/15548627.2015.1042195","article-title":"HK2\/hexokinase-II integrates glycolysis and autophagy to confer cellular protection","volume":"11","author":"Tan","year":"2015","journal-title":"Autophagy"},{"issue":"41","key":"10.1016\/j.biomaterials.2026.124026_bib33","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.2174\/0929867326666181213092652","article-title":"Unlocking the potential of HK2 in cancer metabolism and therapeutics","volume":"26","author":"Garcia","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124026_bib34","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.bbadis.2018.01.002","article-title":"Aggressive triple negative breast cancers have unique molecular signature on the basis of mitochondrial genetic and functional defects","volume":"1864","author":"Guha","year":"2018","journal-title":"Biochimica et biophysica acta. Molecular basis of disease"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124026_bib35","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","article-title":"Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I\u03baB\u03b1","volume":"34","author":"Guo","year":"2022","journal-title":"Cell Metab."},{"issue":"47","key":"10.1016\/j.biomaterials.2026.124026_bib36","doi-asserted-by":"crossref","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"Maute","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124026_bib37","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1021\/acsnano.0c01350","article-title":"3-Bromopyruvate-Conjugated nanoplatform-induced pro-death autophagy for enhanced photodynamic therapy against hypoxic tumor","volume":"14","author":"Deng","year":"2020","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124026_bib38","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.5012\/bkcs.2013.34.6.1800","article-title":"Chemoenzymatic synthesis of dual-responsive amphiphilic block copolymers and drug release studies","volume":"34","author":"Chen","year":"2013","journal-title":"Bull. Kor. Chem. Soc."},{"issue":"5\u20136","key":"10.1016\/j.biomaterials.2026.124026_bib39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/bip.20743","article-title":"Novel amphiphilic ternary polysaccharide derivates chitosan-g-PCL-b-MPEG: synthesis, characterization, and aggregation in aqueous solution","volume":"86","author":"Lu","year":"2007","journal-title":"Biopolymers"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/bm0101163","article-title":"Chemoselective protection of the amino groups of chitosan by controlled phthaloylation: facile preparation of a precursor useful for chemical modifications","volume":"3","author":"Kurita","year":"2002","journal-title":"Biomacromolecules"},{"issue":"46","key":"10.1016\/j.biomaterials.2026.124026_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202107883","article-title":"Cancer-cell-biomimetic nanoparticles for targeted therapy of multiple myeloma based on bone marrow homing","volume":"34","author":"Qu","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124026_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biomaterials.2014.10.036","article-title":"Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers","volume":"38","author":"Miteva","year":"2015","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124026_bib43","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"5930","key":"10.1016\/j.biomaterials.2026.124026_bib44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Heiden","year":"2009","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124026_bib45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cac2.12549","article-title":"The regulatory roles and clinical significance of glycolysis in tumor","volume":"44","author":"Qiao","year":"2024","journal-title":"Cancer Commun."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124026_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tibs.2018.10.011","article-title":"Lactate: a metabolic driver in the tumour landscape","volume":"44","author":"Ippolito","year":"2019","journal-title":"Trends Biochem. Sci."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124026_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124026_bib49","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.celrep.2018.07.062","article-title":"Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion","volume":"24","author":"Liu","year":"2018","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124026_bib50","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41556-023-01185-x","article-title":"STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2","volume":"25","author":"Zhang","year":"2023","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124026_bib51","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124026_bib52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:10:31Z","timestamp":1782187831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S0142961226000505"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124026","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically engineered cellular membrane-camouflaged nanoparticles amplify immune response against recurrent metastatic triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124026"}}